Fig. 9

Neuropeptide signaling minimally contributed to post fracture popliteal lymphadenopathy. Changes in size of the popliteal lymph node at 3 weeks after fracture (FX) in wildtype (WT), SP-deficient (Tac1^−/−), and CGRP receptor-deficient (RAMP1^−/) mice. Representative popliteal lymph node images are presented from an a intact wildtype (WT-NO FX), b ipsilateral (WT-FX-IPSI), and c contralateral (WT-FX-CONTRA) to fracture in a wildtype mouse. d At 3 weeks post fracture, there was 97% increase in lymph node diameter (WT-FX-IPSI-wk3) vs WT-NO FX controls (1.9 ± 0.1 mm vs 0.96 ± 0.1 mm) and this increase persisted at 7 weeks after fracture (WT-FX-IPSI-wk7, 1.5 ± 0.4 mm). e The increase in popliteal lymph node size in substance P-deficient fracture mice (Tac1^−/−-FX-IPSI) 11% less than that of WT-FX-IPSI. f The increase in popliteal lymph node size in CGRP receptor-deficient fracture mice (RAMP1^−/-FX-IPSI) was 16% less than that of WT-FX-IPSI. Data were analyzed using a one-way analysis of variance (ANOVA) with Bonferroni correction test for post hoc contrasts, error bars indicate SEM, n = 6 per cohort. **P < 0.01, ***P < 0.001 vs. WT-NO FX, # P < 0.05, ##P < 0.01 and ###P < 0.001 vs. FX-IPSI-wk3 or WT-FX-IPSI, &&& P < 0.001 vs. the respective unfractured control mice (i.e., either Tac1^−/−-NO FX or RAMP1^−/−-NO FX), $$$ P < 0.001 vs. the respective fractured knockout mice (i.e., either Tac1^−/−- FX-IPSI or RAMP1^−/−- FX-IPSI). Scale bar = 250 μm